Wirkort vieler Arzneistoffe

1. Noreng, S., Li, T., Payandeh, J., Structural Pharmacology of Voltage-Gated Sodium Channels. J. Mol. Biol. 433 (2021) 166967.
2. Tao, E., Corry, B., Characterizing fenestration size in sodium channel subtypes and accessibility to inhibitors. Biophys. J. 121 (2022) 193–206.
3. Tikhonov, D. B., Zhorov, B. S., Mechanism of Sodium channel block by local anesthetics, antiarrhythmics and anticonvulsants. J. Gen. Physiol. 149 (017) 465–481.
4. Palmisano, V. F., et al., Voltage-Gated Ion Channels: Structure, Pharmacology and Photopharmacology. ChemPhysChem. 25 (2024) e202400162.
5. Alsaloum, M., et al., Voltage-gated sodium channels in excitable cells as drug targets. Nat. Rev. Drug. Discov. 24 (2025) 358–378.
6. Buyan, A., Whitfield, A. A., Corry, B., Differences in local anaesthetic and antiepileptic binding in the inactivated state of human sodium channel. Na _v 1.4. Biophys. J. 120 (2021) 5553–5563.
7. Medyanik, A. D., et al., Developmental and Epileptic Encephalopathy: Pathogenesis of Intellectual Disability Beyond Channelopathies. Biomolecules 15 (2025) 133.
8. Johnson, J. P., et al., NBI-921352, a first-in-class, Na _v 1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats. eLife 11 (2022) e72468.
9. Kahlig, K. M., et al., The novel persistent sodium current inhibitor PRAX-562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers. Epilepsia 63 (2022) 697–708.
10. www.neurologylive.com/view/breakthrough-therapy-designation-granted-relutrigine-scn2a-scn8a-developmental-epileptic-encephalopathies (gelesen am 19.8.2025).
11. Desaphy, J. F., et al., Safinamide’s potential in treating nondystrophic myotonias: Inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo. Exp Neurol. 328 (2020) 113287.
12. Deng, L., et al., Na _v 1.7 is essential for nociceptor action potentials in the mouse in a manner independent of endogenous opioids. Neuron 111 (2023) 2642–2659.e13.
13. Kschonsak, M., et al., Cryo-EM reveals an unprecedented binding site for Na _v 1.7 inhibitors enabling rational design of potent hybrid inhibitors. elife 12 (2023) e84151.
14. Osteen, J. D., et al., Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective Nav1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain. Pain Ther. 14 (2025) 655–674.
15. Keam, S. J., Suzetrigine: First Approval. Drugs 85 (2025) 845–851.

Ulrike Holzgrabe studierte Chemie und Pharmazie in Marburg und Kiel und habilitierte sich in Pharmazeutischer Chemie in Kiel. Nach mehrjähriger Professorentätigkeit in Bonn ist sie seit April 1999 als Professor in Würzburg tätig, seit Mitte 2022 als Emerita. Professor Holzgrabe war von 2018 bis 2021 Vizepräsidentin der Universität Würzburg. In vielfältigen Positionen arbeitete sie am Deutschen und Europäischen Arzneibuch am BfArM und EDQM mit. Seit vielen Jahren forscht sie auf dem Gebiet der Antibiotika und der Analytik.